News

orange__line
MedSIR INSIDE OUT – Duna Zaragoza

Today we are happy to spend a brief moment with Duna Zaragoza, Head of Human Resources at MedSIR…we all known her as People Manager. MedSIR Newsletter Team (MS): Thanks Duna, for spending...
READ MORE...
Post ESMO 2018

October 19th was the first day of the annual meeting of the European Society of Molecular Oncology. Nearly 20,000 oncology stakeholders from over 130 countries worldwide attended the conference in Munich, Germany, and the MedSIR team was...
READ MORE...
MedSIR at BIO-EUROPE 2018

The 24th annual BIO-Europe will kick off on November 4th for three intense days of high level networking in Copenhagen. BIO-Europe is Europe´s largest biotech and pharma partnering conference. This year it will bring together more than 4,000 industry attendees...
READ MORE...
The AZENT Study

We are pleased to announce that AZENT study "A phase IIa clinical trial to evaluate the safety and efficacy of osimertinib (AZD9291) in first-line patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer...
READ MORE...
MedSIR INSIDE OUT – Christian Gonzalez

Today we are happy to interview our new Business Development guy, Christian Gonzalez. MedSIR Newsletter Team (MS): Thanks, Christian, for spending some time with us here today. Christian Gonzalez (CG)...
READ MORE...
The Kelly Study

This a multicenter, open-label, phase II clinical trial to assess the efficacy of pembrolizumab in combination with eribulin in female patients with hormone receptor-(HR) positive/HER2-negative metastatic breast cancer (MBC) previously treated with...
READ MORE...
The BioPER study

“A Multicentre, International, Non-controlled Phase II Trial to Identify the Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge Upon Progression to a Palbociclib Combination in ER-positive Metastatic Breast Cancer...
READ MORE...
The PHERGain Study

We are pleased to announce that PHERGain study “Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive (Human Epidermal Receptor) Breast Cancer: FDG-PET Response-adapted Strategy” has achieved 40% of recruitment!!
READ MORE...
Dietary supplements and cancer: promises and realities

A dietary supplement can be defined as any vitamin, mineral, protein, enzyme, probiotic, herb, or plant substance taken to supplement dietary needs or improve body functions. Although some dietary supplements...
READ MORE...